Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: Chemotherapy-induced peripheral neurotoxicity (CIPN) affects nearly 70% of cancer patients after chemotherapy, causing sensory, motor, autonomic dysfunction, and neuropathic pain. The Desirability of Outcome Ranking (DOOR) framework is proposed as a better way to assess preventive or therapeutic interventions for CIPN.

Methods: A survey was conducted among Italian healthcare professionals and researchers affiliated to the Italian Chapter of the International Association for the Study of Pain (AISD) to identify the most important outcomes in clinical management and research.

Results: Among the 73 respondents, 61 qualified for the survey, with an overall response rate of 1.2%. The vast majority were physicians (77%), most of whom were anesthesiologists (47.5%). The results showed that pain, survival, sensory impairment, motor impairment, and quality of life were consistently ranked as the most important outcomes, but there was significant disagreement in the outcomes relative ranking, making it difficult to develop a DOOR algorithm. The study also revealed that clinicians commonly use structured interviews to evaluate patients with CIPN, and the most prescribed drugs or supplements were palmitoylethanolamide, pregabalin, gabapentin and alpha lipoic acid as preventive agents and pregabalin, palmitoylethanolamide, duloxetine, gabapentin, and amitriptyline as therapeutic agents. However, many of these drugs have not been clinically proven to be effective for CIPN.

Discussion: This study suggests that the implementation of a DOOR framework for CIPN using healthcare professionals is more difficult than expected, given the significant disagreement in our respondents' ranking of outcomes. Our work provides interesting topics for future research in CIPN, but its limitations include a small sample size, a low response rate, and a possible selection bias.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542526PMC
http://dx.doi.org/10.2147/JPR.S414389DOI Listing

Publication Analysis

Top Keywords

chemotherapy-induced peripheral
8
peripheral neurotoxicity
8
association study
8
study pain
8
door framework
8
healthcare professionals
8
response rate
8
exploring outcome
4
outcome priorities
4
priorities real-life
4

Similar Publications

Mechanisms and treatment of cancer therapy-induced peripheral and central neurotoxicity.

Nat Rev Cancer

September 2025

Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.

Neurotoxicity is a common and potentially severe adverse effect from conventional and novel cancer therapy. The mechanisms that underlie clinical symptoms of central and peripheral nervous system injury remain incompletely understood. For conventional cytotoxic chemotherapy or radiotherapy, direct toxicities to brain structures and neurovascular damage may result in myelin degradation and impaired neurogenesis, which eventually translates into delayed neurodegeneration accompanied by cognitive symptoms.

View Article and Find Full Text PDF

Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity associated with oxaliplatin-based chemotherapy in gastric cancer patients. Recent studies suggest that high-dose intravenous selenium may exert neuroprotective effects in patients receiving platinum-based chemotherapy.

Methods: This pilot study analyzed patients with stage III gastric adenocarcinoma who underwent gastrectomy between January and December 2024.

View Article and Find Full Text PDF

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and often persistent adverse effect of several anticancer agents, leading to impaired physical function and quality of life. Although exercise therapy and physical modalities such as transcutaneous electrical nerve stimulation have been reported to alleviate CIPN symptoms, the efficacy of alternating magnetic field therapy remains unclear. We here report a rectal cancer survivor who experienced difficulty returning to work due to persistent neuropathic symptoms of CIPN.

View Article and Find Full Text PDF

Objective: To explore the trajectory patterns and influencing factors of chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients using latent class growth analysis (LCGA).

Methods: This study was conducted from September 2022 to September 2023 at a tertiary hospital in Tangshan, China. A total of 350 hospitalized breast cancer patients undergoing chemotherapy were recruited.

View Article and Find Full Text PDF

The Most recent updates on pectin in Cancer therapy: A review.

Int J Biol Macromol

September 2025

Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, P.O. Box 11562, Egypt. Electronic address:

Pectin is a structurally diverse, plant-derived polysaccharide primarily obtained from apple pomace and citrus fruits. Its biocompatibility, modifiability, and multiple bioactivities have attracted increasing interest for potential applications in cancer therapy. This review summarizes modification techniques that enhance pectin's physicochemical and biological properties, elucidates its main anticancer mechanisms, and highlights recent advances (2020-2025) in its therapeutic potential.

View Article and Find Full Text PDF